A clinical study to compare the efficacy and safety of masitinib 4.5 mg/kg/day vs. placebo in the treatment of patients with multiple sclerosis
- Conditions
- Primary progressive or relapse-free secondary progressive multiple sclerosisMedDRA version: 14.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2010-021219-17-GR
- Lead Sponsor
- AB Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 450
1. Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald’s criteria
2. Patient with EDSS score of [2.0 to 6.0] inclusive at baseline
3. Patient who had an EDSS score progression = 1 point within 2 years before inclusion
4. Patient with normal organ function defined as:
•Absolute neutrophils count (ANC) = 2 x 109/L
•Hemoglobin = 10 g/dL
•Platelets (PTL) = 100 x 109/L
•AST/ALT = 2.5x ULN
•Bilirubin = 1.5x ULN
•Creatinine clearance > 60 mL/min (Cockcroft and Gault formula)
•Albumin = 1 x LLN
•Urea = 1.5 x ULN
•Proteinuria < 30 mg/dL on dipstick; in case of the proteinuria = 30 mg/dL, 24 hours proteinuria < 1.5g/24 hours
5. Male or female patient, aged > 18, at time of informed consent signature
6. Patient able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months of treatment.
7. Man and woman of childbearing potential (entering the study after a menstrual period, and who have a negative pregnancy test) must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake
8. Patient able and willing to comply with study procedures as per protocol
9. Patient able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 350
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100
1. Patient suffering from a disease other than MS that would better explain the patient’s neurological clinical signs and symptoms and/or MRI lesions
2. Patient who had a major surgery within 2 weeks of study entry
3. Patient with life expectancy < 6 months
4. Patient with history of primary malignancy < 5 years, except treated basal cell skin cancer or cervical carcinoma in situ
5. Patient presenting with cardiac disorders defined by at least one of the following conditions:
Patient with recent cardiac history (within 6 months) of:
- Acute coronary syndrome
- Acute heart failure (class III or IV of the NYHA classification)
- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- Patient with cardiac failure class III or IV of the NYHA classification
- Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
-Syncope without known aetiology within 3 months
- Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
6. Patient with any severe and/or uncontrolled medical condition
7. Patient with a known diagnosis of human immunodeficiency virus (HIV) infection
8. Patient with known active hepatitis B, hepatitis C or tuberculosis
9. Pregnant or nursing female
10. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
11. Patient with any condition or concurrent medical events, including any clinically significant deviations from reference ranges in laboratory test, that on the opinion of the physician could be detrimental to the subjects
PREVIOUS TREATMENT WASH OUT
12. Previous treatment with immunomodulators and/or immunosuppressors treatments including azathioprine, cladribine, cyclophosphamide, cyclosporine, methotrexate, mitoxantrone, natalizumab, mycophenolate mofetil, hematopoietic stem cell transplantation, plasma exchange or total lymphoid irradiation within 24 weeks prior to baseline
13. Interferon, glatiramer acetate, IV infusion of immunoglobulins or monthly bolus IV corticosteroids within 12 weeks prior to baseline
14. Treatment with any oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 4 weeks prior to baseline
15. Treatment with any investigational drug within 12 weeks prior to baseline
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method